CytoDyn is a clinical-stage biotechnology company developing leronlimab, an investigational humanized monoclonal antibody targeting the CCR5 receptor. CytoDyn has no approved products and generates no revenue from product sales. The company focuses primarily on oncology, using leronlimab to disrupt tumor progression and metastatic spread while modulating the tumor immune microenvironment in solid tumors. Its primary development programs target metastatic colorectal cancer, evaluated in Phase 2 combination trials, and metastatic triple-negative breast cancer. CytoDyn also conducts early-stage exploratory research in glioblastoma and collaborates on longer-acting CCR5 antagonists. CytoDyn maintains a lean workforce and no internal manufacturing facilities, relying entirely on contract research organizations and contract manufacturing organizations for clinical development and drug supply. The company funds operations through equity financings and seeks licensing agreements, co-development partnerships, and strategic collaborations to advance clinical trials toward regulatory approval and commercialization.